Business Strategy

What are you looking for?

Solutions
Probiotic Portfolio
Probi Defendum® Probi Ferrosorb® Probi Digestis® Probi® Osteo Probi Livebac®
Health Positions
Digestive Health Immune Health Bone Health Iron Absorption Women's Health Senior Health Children's Health
Application Areas
Dietary Supplements Food & beverages
The LP299V® Strain
Why Probi
Adding value
Customization
Manufacturing
Manufacturing Process Production sites FAQ - probiotics manufacturing
Quality
Partnership
Our Research
Clinical Studies
Our Expertise
Scientific Collaboration
Knowledge
Contact
Product request
Investor Relations
Read this in Swedish
The Share Press Releases Financial reports Business Strategy Financial Goals Key Figures Investment Case Management & Board of Directors Corporate Governance Presentations Financial Calendar
About Us
History Career Sustainability News and Events
English
中文
Home Investor Relations Business Strategy

Contact

Probi Henrik Lundkvist 2022 240X240

Henrik Lundkvist

CFO

Send mail

Overall Goal:
Doubled sales

Strategy:
Organic growth and strategic acquisitions

  • Stronger position in scientifically validated products for gastrointestinal and immune health
  • Increased presence in the US, China and other growth markets
  • Greater number of key global customers
  • More strategic partnerships and acquisitions in relevant geographies and segments

 

Overall Goal:
Lead the way in innovation and development

Strategy:
Higher development rate of new products

  • Expanded range with more clinically documented offers
  • Higher number of international research collaborations
  • Evaluation of growth potential in areas related to probiotics

Overall Goal:
Manufacturing excellence

Strategy:
Efficient manufacturing

  • Facilities with guaranteed high-quality production capacity, adapted to market needs
  • New manufacturing capabilities in growth regions
  • Focus on long-term improved gross margins